RxDoctor Payments Data

Karen Conoboy, APRN

Nurse Practitioner · Westmont, ILNPI 1467035881

Payments from drug & device makers

$9,138in general payments, 2019–2025

Across 334 payments — averaging $27.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$2K
  • Novartis$1K
  • AstraZeneca$737
  • Alnylam Pharmaceuticals Inc.$503
  • Boston Scientific$448
  • Abbott$440
  • plus $4K from 23 others

What the payments were for

  • Food & beverage$9,124100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,138 in reported general payments places this provider in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$160,663
Medicare patients
360
Services billed
3,658

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin403$420,778
EntrestoSacubitril/Valsartan308$387,634
EliquisApixaban163$197,865
FarxigaDapagliflozin Propanediol159$156,572
XareltoRivaroxaban40$40,288
Torsemide299$7,159
Metoprolol Succinate261$4,833
Eplerenone51$2,294
Spironolactone288$2,082
Atorvastatin Calcium170$1,831
Furosemide267$1,690
Hydralazine Hcl58$1,239
Amiodarone Hcl46$1,228
Losartan Potassium89$978
Carvedilol87$891

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$2,421$420,778403 claims
NovartisEntresto$1,086$387,634308 claims
PfizerEliquis$254$197,865163 claims
AstraZenecaFarxiga$737$156,572159 claims
Johnson & JohnsonXarelto$186$40,28840 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Westmont

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →